Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2006-10-10
2006-10-10
Weber, Jon (Department: 1653)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C530S412000, C530S417000, C530S427000, C435S069100, C435S252300, C435S320100
Reexamination Certificate
active
07119166
ABSTRACT:
A universal folding method that has been demonstrated to be effective in refolding a variety of very different proteins expressed in bacteria as inclusion bodies has been developed. Representative proteins that can be dissolved and refolded in biologically active form, with the native structure, are shown in Table I. The method has two key steps to unfold and then refold the proteins expressed in the inclusion bodies. The first step is to raise the pH of the protein solution in the presence of denaturing agents to pH greater than 9, preferably 10. The protein solution may be maintained at the elevated pH for a period of up to about 24 hours, or the pH immediately decreased slowly, in increments of about 0.2 pH units/24 hours, until the solution reaches a pH of about 8.0, or both steps used. In the preferred embodiment, purified inclusion bodies are dissolved in 8 M urea, 0.1 M Tris, 1 mM glycine, 1 mM EDTA, 10 mM beta-mercaptoethanol, 10 mM dithiothreitol (DTT), 1 mM reduced glutathione (GSH), 0.1 mM oxidized glutathione (GSSG), pH 10. The absorbance at 280 nm (OD280) of the protein solution is 5.0. This solution is rapidly diluted into 20 volumes of 20 mM Tris base. The resulting solution is adjusted to pH 9.0 with 1 M HCl and is kept at 4° C. for 24 hr. The pH is adjusted to pH 8.8 and the solution is kept at 4° C. for another 24 hrs. This process is repeated until the pH is adjusted to 8.0. After 24 hr at pH 8.0, the refolded proteins can be concentrated by ultrafiltration and applied to a gel filtration column for purification.
REFERENCES:
patent: 4518526 (1985-05-01), Olson
patent: 6545127 (2003-04-01), Tang et al.
patent: 6583268 (2003-06-01), Lin
patent: 2001/0044521 (2001-11-01), Lin
patent: 2002/0049303 (2002-04-01), Tang et al.
patent: 2002/0115600 (2002-08-01), Koelsch et al.
patent: 2002/0164760 (2002-11-01), Lin et al.
patent: 2004/0167075 (2004-08-01), Tang et al.
patent: 2004/0220079 (2004-11-01), Koelsch et al.
patent: 2004/0265298 (2004-12-01), Lin
patent: WO 01/00663 (2001-01-01), None
patent: WO-01/55174 (2001-08-01), None
patent: WO-01/55174 (2001-08-01), None
patent: WO-2004/094344 (2004-11-01), None
patent: WO-2005/058930 (2005-06-01), None
Chen, “Recombinant rhizopuspepsingen,” J Biol Chem 266(18):11718-11725 (1991).
Cheng, et al., “High-level synthesis of recombinant HIV-1 protease and the recovery of active enzyme from inclusion bodies,” Gene 87:243-248 (1990).
Ermolieff, et al., “Kinetic properties of saquinavir-resistant mutants of human immunodeficiency virus type 1 protease and their implications in drug resistance in vivo,” Biochemistry 36(40):12364-12370 (1997).
Fusek, et al., “Enzymic properties of thermopsin,” J Biol Chem 265(3):1496-1501 (1990).
Ghosh, et al., “Design of potent inhibitors for human brain memapsin 2 (□-secretase),” J Am Chem Soc 122:3522-3523 (2000).
Huxtable, et al., “Renaturation of 1-aminocyclopropane-1-carboxylate synthesis expressed inE. coli.in the form of inclusion bodies into a dimeric and catalytically active enzyme,” Protein Expression and Purification 12(3):305-314 (1998).
Kelley & Winkler, “Folding of eukaryotic proteins produced inE. coli,” Genetic Engineering 12:1-19 (1990).
Koelsch, et al., “Enzymic characteristics of secreted aspartic proteases ofCandida albicans,” Biochemica et Biophysica Acta 1480:117-131 (2000).
Lin & Tang, “Purification, characterization, and gene cloning of thermopsin, a thermostable acid protease from Sulfolobus acidocaldarius,” J Biol Chem 265(3):1490-1495 (1990).
Lin, “Construction of new retroviral producer cells from adenoviral and retroviral vectors,” Gene Therapy 5:1251-1258 (1998).
Lin, et al., “Conformational instability of the N- and C- terminal lobes of porcine pepsin in neutral and alkaline solutions,” Protein Science 2:1383-1390 (1993).
Lin, et al., “Effect of point mutations on the kinetic and the inhibition of human immunodefiency virus type 1 protease: Relationship to drug resistance,” Biochemistry 34(4):1143-1152 (1995).
Lin, et al., “Enzymatic activities of two-chain pepsinogen, two-chain pepsin, and the amino-terminal lobe of pepsinogen,” J Biol Chem 267(24):17257-17263 (1992).
Lin, et al., “Heterologous expression of thermopsin, a heat-stable acid proteinase,” Enzyme Microb Technol 14:696-701 (1992).
Lin, et al., “Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein,” Proc. Natl. Acad. Sci USA 97(4):1456-1460 (2000).
Lin, et al., “Intracellular diversion of glycoprotein GP160 of human immunodeficiency virus to lysosomes as a strategy of AIDS gene therapy,” FASEB Journal 7:1070-1080 (1993).
Lin, et al., “pH dependence of kinetic parameters of pepsin, rhizopuspepsin, and their active-site hydrogen bond mutants,” J Biol Chem 267(26):18413-18418 (1992).
Lin, et al., “Recombinant canditropsin, an extracellular aspartic protease from yeastCandida tropicals,” J Biol Chem 268(27):20143-20147 (1993).
Lin, et al., “Relationships of human immunodeficiency virus protease with eukaryotic aspartic protease,” Methods in Enzymology 241:195-224 (1994).
Lin, et al., “Synthesis, purification, and active site mutagenesis of recombinant porcine pepsinogen,” J Biol Chem 264(8):4482-4489 (1989).
Reed, et al., “Alteration of glycosylation renders HIV sensitive to inactivation by normal human serum,” J Immunology 159:4359-4361 (1997).
Roswell, “Lysosome-associated membrane protein-1-mediated targeting of the HIV-1 envelope protein to an endosomal/lysosomal compartment enhances its presentation to MHC Class II-restricted T cells,” J Immunology 155:1818-1828 (1995).
Tang & Lin, “A new anti-HIV gene therapy strategy—Diversion of gp160 to lysosomes,” International Antiviral News 2(2):19-20 (1994).
Tang & Lin, “Engineering aspartic proteases to probe structure and function relationships,” Current Opinion in Biotechnology 5:422-427 (1994).
Tang, et al., “Understanding HIV protease: Can it be translated into effective therapy against AIDS?” Scand J Clin Lab Invest Suppl 210:127-35 (1992).
Tichy, et al., “Improved procedure for high-yield recovery of enzymatically active recombinant calf chymosin fromE. coliinclusion bodies,” Protein Expression and Purification 4(1):59-63 (1993).
Wang, et al., “Crystal structure of the catalytic domain of human plasmin complexed with streptokinase,” Science 281:1662-1665 (1998).
Wang, et al., “Human plasminogen catalytic domain undergoes an unusual conformational change upon activation,” J Mol. Biol 295:903-914 (2000).
Wei, et al., “Oxidative refolding of recombinant prochymosin,” Biochem. J. 340:345-351 (1999).
Fischer, B. et al. (1993). “Isolation, Renaturation, and Formation of Disulfide Bonds of Eukaryotic Proteins Expressed inEscherichia colias Inclusion Bodies,”Biotechnology and Bioengineering41:3-13.
Lin, X. U.S. Appl. No. 11/011,406 filed Dec. 13, 2004.
Mitra Rita
Morrison & Foerster / LLP
Oklahoma Medical Research Foundation
Weber Jon
LandOfFree
Universal procedure for refolding recombinant proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Universal procedure for refolding recombinant proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Universal procedure for refolding recombinant proteins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3685739